Sarcos Technology and Robotics Corporation Announces First Quarter 2022 Financial Results
Sarcos Technology and Robotics Corporation (NASDAQ: STRC, STRCW) announced the acquisition of RE2, Inc., enhancing its engineering capabilities. For Q1 2022, total revenue decreased to $0.7 million from $1.8 million in Q1 2021. Operating expenses surged to $26.4 million, primarily due to increased stock-based compensation and acquisition costs. The net loss expanded to $19.2 million from $5.2 million in the prior year. Sarcos maintains its expectation to commence production of its Guardian series robots by the end of 2022, with $199 million in cash reserves as of March 31, 2022.
- Acquisition of RE2, aimed at enhancing engineering capacity.
- Expected commencement of Guardian XO and XT commercial production by end of 2022.
- $199 million in unrestricted cash provides substantial liquidity.
- Revenue declined from $1.8 million to $0.7 million year-over-year.
- Operating expenses increased sharply to $26.4 million, largely due to stock-based compensation.
- Net loss widened to $19.2 million compared to $5.2 million in Q1 2021.
Announced acquisition of RE2, Inc.
Ended the first quarter with
Initial production of commercial units of Guardian® XO® industrial exoskeleton and Guardian® XT™ teleoperated dexterous robotic system still expected to commence by the end of 2022
SALT LAKE CITY, May 11, 2022 (GLOBE NEWSWIRE) -- Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC and STRCW), a leader in the development of highly dexterous robotic systems that augment humans to enhance productivity and safety, today announced financial results for the quarter ending March 31, 2022.
Recent highlights include:
- Announced the successful closing of the previously announced acquisition of RE2, Inc., bringing together two of the most experienced commercial robotics teams and nearly doubling the size of Sarcos’ engineering team
- RE2 announced a developmental partnership with JLG Industries, Inc. to integrate RE2 Sapien™ robotic arm technology with JLG access equipment
- Carried out demonstrations of Guardian® XT™ highly dexterous teleoperated robot functionality to both government and commercial customers including the use of off-the-shelf grinding, buffering, and welding tools
“Our most recent key development was the announcement of our acquisition of RE2,” said Kiva Allgood, President and CEO, Sarcos. “A second development location in Pittsburgh, one of the nation’s leading robotics centers, as well as the addition of RE2’s world class engineering team will allow us to meet the needs of more customers and offer solutions to a wider range of use cases. The combination of RE2 and Sarcos is great news for our employees, partners, customers, and stockholders,” said Allgood.
Financial results
Total revenue was
Total operating expenses for the first quarter were
Research and development expenses were higher compared to the prior year period due to increased headcount and overhead resulting from investments to develop and commercialize our Guardian XO industrial exoskeleton and Guardian XT teleoperated dexterous robotic system. These expenditures were focused on the recruitment of new team members, particularly in engineering and supply chain, and investments in manufacturing capabilities.
The first quarter 2022 net loss was
Excluding certain items, first quarter non-GAAP net loss was
Sarcos ended the quarter with
Development outlook and financial guidance
In line with previous guidance, Sarcos continues to expect to commence initial production of commercial units of its Guardian XO industrial exoskeleton and Guardian XT robotic system by the end of 2022 for delivery to customers early in 2023.
Several demonstrations of the Guardian XT robot Beta units to partners and customers have taken place in Sarcos’ facility since the start of the year and the company continues to expect that Guardian XT robot Beta units will be placed with customers for field tests in mid-2022.
As previously announced, functionality testing of key elements of the first Beta Guardian XO industrial exoskeleton is under way and the company continues to expect that Guardian XO robot Beta units will be available for testing in the second half of 2022.
Excluding the impact of the RE2 acquisition, Sarcos continues to believe that its monthly cash used in operating activities and purchases of property and equipment, will average
Due to uncertainty around availability and lead-times, Sarcos has decided to begin sourcing certain materials and components required for the manufacture of its commercial units in 2023. These purchases will not impact the company’s operating expenses for 2022 but are expected to impact the 2022 year-end cash total by up to
Sarcos is still assessing the impact of the acquisition of RE2 on company earnings and cash burn and the guidance discussed above does not include any expectations regarding RE2. Sarcos expects to provide guidance for the combined company on future earnings calls. However, the company continues to believe that the acquisition of RE2 will not materially impact the combined company’s cash burn in the near term.
Webcast
Sarcos will hold a conference call to discuss the first quarter 2022 financial results, along with management’s business outlook, at 5:00 p.m. ET on Wednesday, May 11, 2022. Interested investors can access the webcast at investor.sarcos.com under the events section. A replay will also be available at investor.sarcos.com for one month after the call.
For more information on Sarcos, its leadership team, and its award-winning product portfolio, please visit www.sarcos.com.
About Sarcos Technology and Robotics Corporation
Sarcos Technology and Robotics Corporation (NASDAQ: STRC and STRCW) is a leader in industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity, enable remote operations and reduce operational costs. Sarcos’ mobile robotic systems, including the Guardian® XO®, Guardian® XT™, Guardian® GT, and Guardian® S, along with the Sapien™ family of robotic arms, RE2 Detect™ computer vision software, and RE2 Intellect™ autonomy software, are designed to revolutionize the future of work wherever physically demanding tasks are required. Sarcos is headquartered in Salt Lake City, Utah, and now has a second location in Pittsburgh, PA. For more information, please visit www.sarcos.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including Sarcos’ product roadmap, including the expected timing of product commercialization or new product releases; the expected benefits of the acquisition of RE2 and Sarcos’ ability to realize those benefits; Sarcos’ performance following the acquisition of RE2; customer interest in Sarcos’ products; and Sarcos’ use of and needs for capital. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or “continue” or similar expressions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. These forward-looking statements are based on Sarcos’ management’s current expectations and beliefs, as well as a number of assumptions concerning future events. However, there can be no assurance that the events, results, or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and Sarcos is not under any obligation and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports which Sarcos has filed or will file from time to time with the Securities and Exchange Commission (the “SEC”). In addition to factors previously disclosed in Sarcos’ reports filed with the SEC and those identified in this press release, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: Sarcos’ ability to execute on its business strategy, address staffing shortages and supply chain disruptions, launch its products within expected timelines, develop new products and services and enhance existing products and services; Sarcos’ ability to respond rapidly to emerging technology trends; Sarcos’ ability to compete effectively, recruit and retain qualified personnel and manage growth and costs; the ability to successfully integrate RE2’s operations, personnel, products and technologies; the risk that the anticipated benefits of the planned acquisition of RE2 may not be realized or may take longer than anticipated to be realized, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the economy and competitive factors in the areas where Sarcos and RE2 do business; general competitive, economic, geopolitical and market conditions; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents filed from time to time with the SEC, including Sarcos’ Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022. The documents filed by Sarcos with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.
SARCOS TECHNOLOGY AND ROBOTICS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share data)
| As of | ||||||||
| March 31, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 198,958 | $ | 217,114 | ||||
| Accounts receivable | 800 | 788 | ||||||
| Unbilled receivables | 159 | 221 | ||||||
| Inventories, net | 1,005 | 1,006 | ||||||
| Prepaid expenses and other current assets | 6,969 | 9,202 | ||||||
| Total current assets | 207,891 | 228,331 | ||||||
| Property and equipment, net | 6,841 | 7,051 | ||||||
| Other non-current assets | 460 | 441 | ||||||
| Total assets | $ | 215,192 | $ | 235,823 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,629 | $ | 1,681 | ||||
| Accrued liabilities | 3,867 | 4,480 | ||||||
| Total current liabilities | 5,496 | 6,161 | ||||||
| Warrant liabilities | 7,283 | 13,701 | ||||||
| Other non-current liabilities | 1,988 | 1,999 | ||||||
| Total liabilities | 14,767 | 21,861 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 14 | 14 | ||||||
| Additional paid-in capital | 365,104 | 359,439 | ||||||
| Accumulated deficit | (164,693 | ) | (145,491 | ) | ||||
| Total stockholders’ equity | 200,425 | 213,962 | ||||||
| Total liabilities and stockholders’ equity | $ | 215,192 | $ | 235,823 | ||||
See Sarcos 10-Q filing dated May 11, 2022, for accompanying notes to the condensed consolidated financial statements.
SARCOS TECHNOLOGY AND ROBOTICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(in thousands, except share and per share data)
| Three Months Ended March 31, | |||||||
| | 2022 | 2021 | |||||
| Revenue, net | $ | 743 | $ | 1,799 | |||
| Operating expenses: | |||||||
| Cost of revenue | 488 | 1,202 | |||||
| Research and development | 5,881 | 2,815 | |||||
| General and administrative | 17,792 | 2,314 | |||||
| Sales and marketing | 2,211 | 656 | |||||
| Total operating expenses | 26,372 | 6,987 | |||||
| Loss from operations | (25,629 | ) | (5,188 | ) | |||
| Interest income (expense), net | 11 | (10 | ) | ||||
| Gain on warrant liability | 6,414 | — | |||||
| Other income, net | 2 | — | |||||
| Loss before provision for income taxes | (19,202 | ) | (5,198 | ) | |||
| Provision for income taxes | — | — | |||||
| Net loss | $ | (19,202 | ) | $ | (5,198 | ) | |
| Net loss per share: | |||||||
| Basic and diluted | $ | (0.14 | ) | $ | (0.05 | ) | |
| Weighted-average shares used in computing net loss per share | |||||||
| Basic and diluted | 137,908,690 | 104,059,652 | |||||
See Sarcos 10-Q filing dated May 11, 2022, for accompanying notes to the condensed consolidated financial statements.
SARCOS TECHNOLOGY AND ROBOTICS CORPORATION
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)
(in thousands)
| Three Months Ended March 31, | |||||||
| 2022 | 2021 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (19,202 | ) | $ | (5,198 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Stock-based compensation | 10,850 | 173 | |||||
| Depreciation | 268 | 111 | |||||
| Change in fair value of warrant liability | (6,414 | ) | — | ||||
| Changes in operating assets and liabilities | |||||||
| Accounts receivable | (12 | ) | 985 | ||||
| Unbilled receivable | 62 | (423 | ) | ||||
| Inventories | 1 | (311 | ) | ||||
| Deferred transaction costs | — | (1,427 | ) | ||||
| Prepaid expenses and other current assets | 2,233 | (1,105 | ) | ||||
| Other non-current assets | (18 | ) | 2 | ||||
| Accounts payable | 403 | 454 | |||||
| Accrued liabilities | (616 | ) | 537 | ||||
| Accrued transaction fees | — | 1,133 | |||||
| Deferred rent | (6 | ) | — | ||||
| Other non-current liabilities | (1 | ) | 1,198 | ||||
| Net cash used in operating activities | (12,452 | ) | (3,871 | ) | |||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | (514 | ) | (962 | ) | |||
| Net cash used in investing activities | (514 | ) | (962 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from notes payable | — | 2,000 | |||||
| Proceeds from exercise of stock options | 65 | 20 | |||||
| Shares repurchased for payment of tax withholdings | (5,254 | ) | — | ||||
| Purchase of non-controlling interest | — | (200 | ) | ||||
| Payment of obligations under capital leases | (1 | ) | (1 | ) | |||
| Net cash (used in) provided by financing activities | (5,190 | ) | 1,819 | ||||
| Net decrease in cash, cash equivalents | (18,156 | ) | (3,014 | ) | |||
| Cash, cash equivalents at beginning of period | 217,114 | 33,664 | |||||
| Cash, cash equivalents at end of period | $ | 198,958 | $ | 30,650 | |||
| Supplemental disclosure of non-cash activities: | |||||||
| Purchases of property and equipment included in accounts payable at period-end | $ | — | $ | 45 | |||
| Leasehold improvements paid by lessor | $ | — | $ | 424 | |||
See Sarcos 10-Q filing dated May 11, 2022, for accompanying notes to the condensed consolidated financial statements.
Non-GAAP Financial Measures
To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our financial results, we have presented in this release non-GAAP net loss and non-GAAP net loss per share, each of which are non-GAAP financial measures. Non-GAAP net loss and non-GAAP net loss per share are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies.
We define non-GAAP net loss as our GAAP measured net loss excluding the impacts of stock-based compensation expense, gain on forgiveness of notes payable, gain or loss on change in fair value of derivative instruments and warrant liabilities, expenses related to a business combination and other non-recurring non-operating expenses. We define non-GAAP net loss per share as non-GAAP net loss divided by weighted average outstanding shares.
The most directly comparable GAAP measure to non-GAAP net loss is net loss. The most directly comparable GAAP measure to non-GAAP net loss per share is net loss per share. We believe excluding the impact of the previously listed items in calculating non-GAAP net loss and non-GAAP net loss per share can provide a useful measure for period-to-period comparisons of our core operating performance. We monitor, and have presented in this release, non-GAAP net loss and non-GAAP net loss per share because they are each a key measure used by our management and board of directors to understand and evaluate our operating performance and to establish budgets. We believe non-GAAP net loss and non-GAAP net loss per share help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we include in net loss. Accordingly, we believe non-GAAP net loss and non-GAAP net loss per share provide useful information to investors, analysts and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance.
Non-GAAP net loss and non-GAAP net loss per share are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of non-GAAP net loss and non-GAAP net loss per share rather than net loss and net loss per share, which is for each the most directly comparable financial measure calculated and presented in accordance with GAAP. In addition, the expenses and other items that we exclude in our calculations of non-GAAP net loss and non-GAAP net loss per share may differ from the expenses and other items, if any, that other companies may exclude from non-GAAP net loss and non-GAAP net loss per share when they report their operating results, limiting the usefulness of non-GAAP net loss and non-GAAP net loss per share for comparative purposes.
In addition, other companies may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP net loss and non-GAAP net loss per share as tools for comparison.
The following table reconciles non-GAAP net loss to net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP (in thousands, except share and per share data):
| Three Months Ended March 31, | |||||||
| | 2022 | 2021 | |||||
| Net loss | $ | (19,202 | ) | $ | (5,198 | ) | |
| Non-GAAP adjustments: | |||||||
| Stock-based compensation expense | 10,850 | 173 | |||||
| Gain on warrant liability | (6,414 | ) | — | ||||
| Expenses related to business combinations(1) | 1,473 | 284 | |||||
| Non-GAAP net loss | $ | (13,293 | ) | $ | (4,741 | ) | |
| Net loss per share | |||||||
| Basic and diluted | $ | (0.14 | ) | $ | (0.05 | ) | |
| Non-GAAP net loss per share | |||||||
| Basic and diluted | $ | (0.10 | ) | $ | (0.05 | ) | |
| Weighted-average shares used in computing net loss per share | |||||||
| Basic and diluted | 137,908,690 | 104,059,652 | |||||
(1) Expenses related to our business combinations with RE2, Inc., during 2022, and Rotor Acquisition Corp., during 2021, are included within general and administrative expenses within the condensed consolidated statements of operations and comprehensive loss.
Investor Contact:
Ben Mimmack
Head of Investor Relations
(801) 419-0438
pr@sarcos.com
ir@sarcos.com
FAQ
What are the financial results for Sarcos in Q1 2022?
What is the expected production timeline for Sarcos' Guardian robots?
How much cash does Sarcos have following the first quarter?
What impact did the RE2 acquisition have on Sarcos' finances?
